Compound # | Avg Pe (×10−6 cm/s) | Avg %R | GRK2 IC50 (μM) | GRK5 IC50 (μM) | Reference for IC50 Data |
---|---|---|---|---|---|
Paroxetine | 92 ± 7 | 34 ± 2 | 1.4 | >100 | Waldschmidt et al., 2017 |
258748 | <0.3 | 8 ± 1 | 0.008 | 0.24 | Bouley et al., 2017 |
258747 | 1.2 ± 0.1 | 78 ± 1 | 0.018 | 1.5 | Table 1 |
258208 (14as) | 1.4 ± 0.7 | 46 ± 1 | 0.03 | 7.1 | Waldschmidt et al., 2017 |
224061 | 23 ± 1 | 66 ± 1 | 0.066 | 1.3 | Bouley et al., 2017 |
257284 | <0.5 | 29 ± 2 | 0.10 | 0.50 | Bouley et al., 2017 |
258002 | 18 ± 3 | 69 ± 3 | 0.14 | 3.7 | Bouley et al., 2017 |
GSK180736A | ND | ND | 0.77 | >100 | Waldschmidt et al., 2016 |
224406 (12n) | ND | ND | 0.13 | >100 | Waldschmidt et al., 2016 |
215022 (12 h) | 0.21 ± 0.05 | 5 ± 1 | 0.15 | 0.38 | Waldschmidt et al., 2016 |
257142 (33) | 0.12 ± 0.01 | 6 ± 1 | 0.25 | 0.26 | Waldschmidt et al., 2018 |
Propanolol | 79 ± 10 | 31 ± 2 | NA | NA | |
Atenolol | <0.4 | 8 ± 1 | NA | NA |
NA, not applicable ND, not done; Pe, effective permeability; %R, percent membrane retention.